Who are we

The Consortium groups are based in three of the leading UK universities. Prior to the formation of the Consortium each group had conducted at least one clinical trial for gene therapy. Therefore, our researchers have been at the forefront of this field for over 20 years.

 

 

Consortium Timeline

The Consortium was formed in 2001 on the initiative of the then CF Trust Chief Executive Rosie Barnes. This timeline highlights some of our major achievements during this time including our two clinical trials.

 

 

Profiles of the Consortium Strategy Group

As with any large organisation our biggest asset is our people and their skills, experience and expertise. Prior to the formation of the Consortium, each of the three sites had conducted at least one clinical trial for CF gene therapy. Today the Consortium is managed by our strategy group with representatives bringing together the required clinical, regulatory and scientific skills required to ensure that we meet our goals whilst still achieving optimal results.

 

 

Frequently Asked Questions

Consortium FAQs. All you've ever wanted to know about the UK CFGTC.

 

 

All Trials Registered Initiative

The Consortium has signed the All Trials Petition an iniative aimed at encouraging the results of all clinical trials to be made public. The Campaign calls for action from governments, regulators and research bodies to implement measures to ensure trials past and present should be registered, and the full methods and the results reported.

 

 

Contact Details

Consortium Contact Details

 

 

About this Website

The Consortium website and our social media accounts are maintained by our some of our Oxford team. The front end uses Twitter Bootstrap 3 giving a responsive layout accross a range of platforms and screen sizes. Sadly though we are aware that it doesn’t work very well on some versions of Internet Explorer.

 

 

 

Sheep lung parenchyma (cell nuclei blue) transduced with an adenoviral vector (green).

 

Proposed 3D model of the CFTR protein.